Copyright
©The Author(s) 2016.
World J Hepatol. Mar 8, 2016; 8(7): 368-375
Published online Mar 8, 2016. doi: 10.4254/wjh.v8.i7.368
Published online Mar 8, 2016. doi: 10.4254/wjh.v8.i7.368
Table 2 Prevalence of reasons for hepatitis C virus non-treatment in patients with human immunodeficiency virus/hepatitis C virus co-infection
| Total | Race/ethnicity | ||||
| (n = 171) | African-American(n = 126) | Caucasian(n = 32) | Hispanic/other(n = 13) | P value1 | |
| ≥ 1 non-modifiable medical reason, n (%) | 85 (49.7) | 64 (50.8) | 14 (43.8) | 7 (53.8) | 0.806 |
| ≥ 1 potentially modifiable medical reason, n (%) | 113 (66.1) | 83 (65.9) | 21 (65.6) | 9 (69.2) | 1.000 |
| ≥ 1 non-medical reason, n (%) | 113 (66.1) | 85 (67.5) | 21 (65.6) | 7 (53.8) | 0.597 |
- Citation: Oramasionwu CU, Kashuba ADM, Napravnik S, Wohl DA, Mao L, Adimora AA. Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection. World J Hepatol 2016; 8(7): 368-375
- URL: https://www.wjgnet.com/1948-5182/full/v8/i7/368.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i7.368